Is BPC-157 FDA Approved?

The short answer

No. BPC-157 is not FDA approved. There is no FDA-approved drug product containing BPC-157, no approved New Drug Application for any indication, and no version of it that is legally marketed as a medicine in the United States. It also does not qualify as a dietary supplement. Because it fits neither category, it exists only in the research-use-only (RUO) space — sold as a laboratory chemical, explicitly not for human consumption.

This is a common point of confusion, because BPC-157 is widely discussed and easy to find for sale. But availability is not the same as approval. For the scientific background on the molecule itself, see the BPC-157 research profile and how BPC-157 works; for the broader legal status, see is BPC-157 legal in 2026?.

What "FDA approved" actually means

"FDA approved" is a specific legal status, not a general seal of quality. For a drug, it means a sponsor submitted a New Drug Application (NDA) — or a Biologics License Application (BLA) for a biologic — and the FDA reviewed substantial evidence that the product is safe and effective for a defined use, that it is manufactured to consistent quality standards, and that its labeling is accurate. Only after that review does a drug earn the right to be marketed for that use.

Crucially, approval is tied to a specific product, made by a specific manufacturer, for a specific indication. There is no such thing as a molecule being "approved" in the abstract, floating free of an application. A substance sold as a bare research chemical — with no sponsor, no application, and no reviewed manufacturing — cannot be FDA approved by definition. That is the situation BPC-157 is in.

It is also worth separating approval from the other way a substance can be legally sold for human use: as a dietary supplement. Supplements are not FDA approved before sale, but they must fit a legal definition (vitamins, minerals, botanicals, amino acids, and certain other dietary ingredients). A synthetic peptide like BPC-157 does not meet that definition, so the supplement route is closed too. We compare these lanes in research peptides vs prescription peptides and list what is actually cleared in FDA-approved peptides.

Why BPC-157 lacks approval — and what approval would require

BPC-157 is a synthetic peptide derived from a sequence found in a protein in gastric juice. Most of the promising data comes from preclinical work — cell and animal studies — rather than the large, controlled human trials that approval demands. No sponsor has taken it through the full clinical pathway, so there is no approved application on file for any indication.

For BPC-157 to become FDA approved, a sponsor would generally have to complete a lengthy, expensive sequence: file an Investigational New Drug (IND) application, run Phase 1 safety trials in humans, then Phase 2 and Phase 3 trials establishing efficacy and safety for a defined use, and finally submit an NDA with manufacturing and quality data for FDA review. That process typically takes many years and substantial funding, and it has not been done for BPC-157.

1. IND application — permission to test the drug in humans, supported by preclinical safety data.
2. Phase 1–3 clinical trials — establishing safety, dosing, and efficacy for a specific indication in people.
3. NDA submission and review — comprehensive evidence plus manufacturing and labeling data the FDA evaluates before any approval.

"Not approved" is not the same as "illegal"

A frequent misreading is to treat "not FDA approved" as meaning "banned" or "illegal to possess." Those are different questions. BPC-157 is not a federally scheduled controlled substance, so it is not illegal to possess in the way a Schedule I or II drug is. What its lack of approval does mean is narrower but important: it cannot be legally marketed or sold as a medicine, it cannot be sold as a dietary supplement, and it cannot be routinely prescribed and dispensed through pharmacies.

That last point trips people up. Because there is no approved BPC-157 drug, a physician has nothing to prescribe in the normal sense, and compounding pharmacies generally cannot make it either — it currently sits in Category 2 of the FDA's interim compounding review. We unpack both in can doctors prescribe BPC-157? and can compounding pharmacies compound BPC-157?.

So the accurate one-line summary is: BPC-157 is unapproved, non-supplement, research-use-only — and sold that way precisely because the approved and supplement channels are both closed. If you want to understand the study literature responsibly, use neutral educational tools like our reconstitution and dosing calculator and reconstitution guide to interpret research methods, and browse the research library for cited profiles.